JP Morgan has recently reduced Editas Medicine Inc (EDIT) stock to Underweight rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 13, 2024, Truist had reduced the ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.38 which represents a decrease of $-0.03 or -2.13% from the prior close of $1.41. The stock opened at $1.41 and touched a low of $1 ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Editas Medicine (EDIT – Research Report) today. The company’s shares closed yesterday ...

CAMBRIDGE, Mass. – Editas Medicine , Inc. (NASDAQ:EDIT), a leader in gene editing technology currently valued at $104 million in market capitalization, has unveiled significant advancements in its in ...

Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease ...

CAMBRIDGE, Mass. – Editas Medicine , Inc. (NASDAQ:EDIT), a leader in gene editing technology currently valued at $104 million in market capitalization, has unveiled significant advancements in ...